Video

Dr Michael Kolodziej Discusses Taking on 2-Sided Risk in OCM After PP4 Results

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc., discusses the move to 2-sided risk in the Oncology Care Model (OCM).

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc., discusses the move to 2-sided risk in the Oncology Care Model (OCM).

Transcript

We're at a transformative time now with the OCM, with performance period 4 results out now with some practices having to either take on 2-sided risk or leave the model. What's the mindset of these practices right now?

You’d have to ask them. So, in general, I think physicians are risk averse. I think it’s pretty clear, and this is based on what [Center for Medicare and Medicaid Innovation] has told us, that a quarter of the practices aren’t close. Those guys are just going to quit. I think for the 35% or so of practices that are on the cusp, the question becomes if you do the math: I get the [Monthly Enhanced Oncology Services], I get the 5% bonus because of the advanced [alternative payment model], how far away am I and how can I manage that risk? And at least the scuttlebutt is that a lot of practices are engaging insurers to protect them from catastrophic loss.

So, they’re buying insurance against a bad outcome, which is not a bad idea because of the fact that we don’t know what therapies are going to come out in the next 5 years. We don’t know what the case mix is likely going to be in the next 5 years, and those are variables we cannot control. So even if you’ve done splendidly until this point, there’s still going to be risk going forward.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo